Editorial: Long COVID in the biomedical sciences, 2026, Kunnath et al.

Chandelier

Senior Member (Voting Rights)
Editorial: Long COVID in the biomedical sciences

Kunnath, Anil Philip; Kavanagh, Owen; Tan, Shing Cheng



With this special issue, the British Journal of Biomedical Science turns its attention to one of the most perplexing medical challenges of the post-pandemic era: Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC). Millions worldwide continue to live with this condition, and health systems are only beginning to consider its long-term consequences.

Manifestations of this condition are heterogeneous (e.g., debilitating fatigue, cognitive dysfunction, persistent respiratory compromise) affecting multiple organ systems. Despite intensive efforts, its underlying pathophysiological mechanisms remain elusive impeding the development of effective therapies.

Against this background, this Special Issue brings together five original research articles addressing this problem from complementary perspectives, encompassing thoracic imaging, carotid body morphology, serological biomarkers, and microbiota-directed treatment.

Read together, they advance a more coherent picture of its pathophysiology and highlight a shared premise: Long COVID cannot be understood through any single disciplinary lens.
​


Web | DOI | British Journal of Biomedical Science | Open Access
 
The five papers are:

VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial

Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant

Carotid Body Size on CT Angiography in Patients With COVID-19 Pneumonia

Evaluating Lung Changes in Long COVID: Ultra-Low‐Dose vs. Standard‐Dose CT Chest

Chest CT Findings at Six Months Following COVID-19 ARDS – Correlation With the mMRC Dyspnea Scale and Pulmonary Function Tests

Read together, they advance a more coherent picture of its pathophysiology and highlight a shared premise: Long COVID cannot be understood through any single disciplinary lens.
Bold words.
 
Translation: We don't have a clue what we are dealing with.
VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial
Translation: We don't have a clue what we are dealing with but, regardless, we remain convinced that our proprietary blend of probiotics® will help fix it*

*results may vary
 
Back
Top Bottom